Abstract
Postoperative 131I treatment for differentiated thyroid cancer (DTC) can create a radiation hazard for nearby persons. The present prospective study aimed to investigate radiation dose rates in 131I-treated DTC patients to provide references for radiation protection. A total of 141 131I-treated DTC patients were enrolled, and grouped into a singular treatment (ST) group and a repeated treatment (RT) group. The radiation dose rate of 131I-treated patients was measured. The rate of achieving discharge compliance and restricted contact time were analyzed based on Chinese regulations. Multivariate logistic regression analysis was used to analyze the independent factors associated with the clearance of radioiodine. The rate of achieving discharge compliance (131I retention < 400 MBq) was 79.8 and 93.7% at day 2 (D2) for the ST and RT groups, respectively, and reached 100% at D7 and D4, respectively. The restricted contact time with 131I-treated patients at 0.5 m for medical staff, caregivers, family members, and the general public ranged from 4 to 7 days. Multivariate logistic regression analysis showed that the 24-h iodine uptake rate was the only significant factor associated with radioiodine clearance. For the radiation safety of 131I-treated DTC patients, the present results can provide radiometric data for radiation protection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agency IAE (2006) Nuclear medicine resources manual. International Atomic Energy Agency. The IAEA, Vienna
Asli IN, Baharfard N, Shafiei B, Tabei F, Javadi H, Seyedabadi M, Nabipour I, Assadi M (2010) Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma. Radiat Prot Dosim 138:376–381
Beck M (2015) Radiation safety in the management of patients undergoing radioactive iodine ablation therapy. Clin J Oncol Nurs 19:44–46
de Carvalho JW, Sapienza M, Ono C, Watanabe T, Guimarães MI, Gutterres R, Marechal MH, Buchpiguel C (2009) Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I) NaI, on an outpatient basis, be safe? Nucl Med Commun 30:533–541
Demir M, Parlak Y, Cavdar I, Yeyin N, Tanyildizi H, Gümüser G, Sayit E, Erees S, Sayman H (2013) The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer. Radiat Prot Dosim 156:25–29
General Administration of Quality Supervision I and Q of the PR of C (2003) Ionizing radiation protection and safety of radiation sources basic standards (GBl8871-2002). China Standard Press, Beijing
Greco A, Borrello MG, Miranda C, Pierotti MA (2009) Molecular pathology of differentiated thyroid cancer. Q J Nucl Med 53:440–454
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133
Jeong KH, Jung JW, Kim CB, Ahn BC, Lee HK, Yoo SJ, Day O, Lee JK (2014) Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy. Health Phys 106:466–474
Kao LS, Green CE (2008) Analysis of variance: is there a difference in means and what does it mean? J Surg Res 144:158–170
Katoh H, Yamashita K, Enomoto T, Watanabe M (2015) Classification and general considerations of thyroid cancer. Ann Clin Pathol 3:1045
Kusakabe K, Yokoyama K, Ito K, Shibuya H, Kinuya S, Ito M, Higashi T, Togawa T, Koizumi K, Yoshimura M, Uchiyama M, Okamoto T, Kanaya S, Kanaya K, Yoneyama T, Ikebuchi H, Yanagida S, Shibata K, Segawa K, Yamamoto A (2012) Thyroid remnant ablation using 1110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy. Ann Nucl Med 26:370–378
Lahfi Y, Anjak O (2015) Evaluation of the release criteria from hospital of thyroid carcinoma patient treated with 131I. Radiat Prot Dosim 171:534–538
Li SLWR. (2008) Nuclear medicine, 7th edn. People’s Health Press, Beijing
Markou P, Chatzopoulos D (2004) Isolation period prediction in patients with differentiated thyroid carcinoma treated after thyroidectomy by radioiodine-131. Hell J Nucl Med 7:195–198
Martin TM, Vasudevan L, Chirayath SS (2015) Correlation between exposure rate and residual activity in felines undergoing 131I thyroid ablation therapy. Health Phys 109:95–103
Monsieurs M, Thierens H, Dierckx RA, Casier K, De Baere E, De Ridder L, De Saedeleer C, De Winter H, Lippens M, van Imschoot S, Wulfrank D, Simons (1998) Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium). Eur J Nucl Med 25:1368–1376
Mountford PJ (1987) Estimation of close contact doses to young infants from surface dose rates on radioactive adults. Nucl Med Commun 8:857–863
Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, Goldsmith SJ, Jadvar H, Marcus CS, Martin WH, Parker JA, Royal HD, Sarkar SD, Stabin M, Waxman AD (2012) The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 53:1633–1651
Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349
U.S. Nuclear Regulatory Commission (1997) Regulatory guide 8.39. release of patients administered with radioactive materials [R]. Office of Nuclear Regulatory Research, Washington D.C.
Vetter RJ (1997) Regulations for radioiodine therapy in the United States: current status and the process of change. Thyroid 7:209–211
Willegaignon J, Malvestiti LF, Guimarães MI, Sapienza MT, Endo IS, Neto GC, Marone M, Sordi GM (2006) 131I effective half-life (Teff) for patients with thyroid cancer. Health Phys 91:119–122
Yama N, Sakata K, Hyodoh H, Tamakawa M, Hareyama M (2012) A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods. Ann Nucl Med 26:390–396
Acknowledgements
This study was supported by a grant from the Guangdong Province Science and Technology Plan Projects (No. 2016A070714008).
Author information
Authors and Affiliations
Corresponding author
Additional information
Pingyan Jin and Huijuan Feng are co-first authors.
Rights and permissions
About this article
Cite this article
Jin, P., Feng, H., Ouyang, W. et al. Radiation dose rates of differentiated thyroid cancer patients after 131I therapy. Radiat Environ Biophys 57, 169–177 (2018). https://doi.org/10.1007/s00411-018-0736-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00411-018-0736-7